Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1068

Related Citations for PubMed (Select 15225368)

1.
2.

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.

Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.

J Am Acad Dermatol. 2006 Jun;54(6):1003-12. Epub 2006 Mar 20.

PMID:
16713454
3.

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Tak PP.

Ann Rheum Dis. 2004 Jul;63(7):769-73.

4.

Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.

Cañete JD, Pablos JL, Sanmartí R, Mallofré C, Marsal S, Maymó J, Gratacós J, Mezquita J, Mezquita C, Cid MC.

Arthritis Rheum. 2004 May;50(5):1636-41.

5.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

6.

Cytokine profiles during infliximab monotherapy in psoriatic arthritis.

Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, Cordiali-Fei P, Berardesca E.

Br J Dermatol. 2005 Sep;153(3):531-6.

PMID:
16120138
7.

Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.

Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A.

Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):371-7.

PMID:
19505391
8.

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.

Arthritis Rheum. 2005 Apr;52(4):1227-36. Erratum in: Arthritis Rheum. 2005 Sep;52(9):2951.

9.

Infliximab monotherapy for refractory psoriasis: preliminary results.

Cassano N, Loconsole F, Amoruso A, Coviello C, Filieri M, Filotico R, Del Vecchio S, Vena GA.

Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):373-80.

PMID:
15461871
10.

Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate.

Kane D, Gogarty M, O'leary J, Silva I, Bermingham N, Bresnihan B, Fitzgerald O.

Arthritis Rheum. 2004 Oct;50(10):3286-95.

11.

Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.

Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E.

Rheumatol Int. 2002 Nov;22(6):227-32. Epub 2002 Sep 4.

PMID:
12426660
12.

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.

Torii H, Nakagawa H; Japanese Infliximab Study investigators.

J Dermatol Sci. 2010 Jul;59(1):40-9. doi: 10.1016/j.jdermsci.2010.04.014. Epub 2010 May 4.

PMID:
20547039
13.

Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.

Markham T, Mathews C, Rogers S, Mullan R, Bresnihan B, Fitzgerald O, Veale DJ, Fearon U.

Br J Dermatol. 2006 Dec;155(6):1191-6.

PMID:
17107388
14.

Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.

Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD.

Ann Rheum Dis. 2004 Feb;63(2):156-61.

15.
16.

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.

Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP.

Ann Rheum Dis. 2008 Aug;67(8):1139-44. Epub 2007 Nov 29.

17.

Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.

Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA.

Semin Arthritis Rheum. 2008 Apr;37(5):293-8. Epub 2007 Sep 21.

PMID:
17888499
18.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
19.

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.

Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.

Arthritis Rheum. 2009 Nov;60(11):3217-24. doi: 10.1002/art.24913.

20.

Infliximab for psoriasis and psoriatic arthritis.

Antoni C, Manger B.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S122-5.

PMID:
12463461
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk